Evotec SE : Strong fundamental newsflow dominates potential one-offs of the cyberattack
>Strong Q1 - confirmation of 2023 guidance is pre cyberattack effects - Due to the cyberattack on April 6, Evotec only published a qualitative quarterly statement on 12 May without providing Q1 figures. The company emphasised that it had a good start into 2023 and confirmed its guidance for 2023. At the same time, Evotec clarified that the guidance does not include possible effects of the cyberattack and that the attack could have a potential impact on the forecast. W...Evotec is a holding company engaged as a drug discovery solutions company providing drug discovery capabilities to pharmaceutical and biotechnology companies as well as to academic institutions. These drug discovery solutions are provided in form of fee-for service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Co. is primarily involved in the areas of neuroscience, pain, metabolic diseases, oncology and inflammation. Co. provides its drug discovery activities under the banners of EVT Execute, EVT Integrate and EVT Innovate. Co.'s operations are divided into two segments: EVT Execute and EVT Innovate.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.